Abivax, created by Truffle Capital, is a clinical-stage company that leverages its antiviral and immune platforms to optimize its drug candidates to cure HIV and treat inflammatory diseases, as well as cancer.
In May and June 2021, phase IIb and IIa clinical trials of ABX464 for the treatment of ulcerative colitis and rheumatoid arthritis were successfully completed. The phase III clinical trial, last step before commercialisation, is expected in 2022 for ABX464 in the treatment of ulcerative colitis.
See website
Synoptical view
- Stock
- Abivax is listed on EURONEXT GROWTH PARIS since june 2015
- Truffle investment
- € 32M
Management team
Partners
In summary
Truffle Capital has created and invested in Abivax to develop two unique platforms that address huge medical needs and a multi-billion dollar market: viral diseases, particularly HIV/AIDS, inflammatory diseases, including digestive system diseases and liver cancer.
They talk about it
We are now moving forward as quickly as possible with our phase 3 plan in ulcerative colitis as well as phase 2b/3 in Crohn’s disease to bring ABX464 to the many patients suffering from inflammatory bowel disease
KEY STEPS
2013
Project financing by Truffle Capital
2015
IPO on the Euronext market
2018
ABX result paving the way for functional HIV healing
2018
20 million structured debt financing with Kreos Capital
2018
Impressive results from the Phase II A clinical trial for ABX464 in oral ulcerative colitis
2019
Sofinova Partners strengthens Abivax's shareholder base
Media
News
